US Edition
Ambio's ibogaine therapy program targets MS, other conditions
Summary by Multiple Sclerosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Ambio's ibogaine therapy program targets MS, other conditions
Ambio Life Sciences has launched a clinical program to test ibogaine — an experimental, naturally occurring psychedelic — for neurodegenerative conditions such as multiple sclerosis (MS). The program aims to […] The post Ambio’s ibogaine therapy program targets MS, other conditions appeared first on Multiple Sclerosis News Today.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium